| 摘要 |
Ovarian, cervical cancer, endometriosis, clear cell renal carcinoma cancers are very heterogeneous diseases which lack robust diagnostic, prognostic and predictive clinical biomarkers. Conventional clinical biomarkers (stages, grades, tumor mass etc) and molecular biomarkers (CA125, KRAS, p53 etc) are not appropriate for early diagnostics, differential diagnostics, prediction and prognosis of the disease outcome for individual patients. The most common type of the human ovarian cancers is human epithelial ovarian cancer (EOC). This cancer is characterized with one of the lowest survival rates compared to other cancers. The present invention relates to an in vitro method for diagnosing epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or predisposition to epithelial ovarian cancer in a subject, the method comprising determining in a sample of the subject gene expression level of at least one gene in the MDS1 and EVI1 complex (MECOM) locus; and/or copy number of at least one gene in the MECOM locus; wherein the level against at least one expression cutoff value and/or copy number against at least one copy number cutoff value are indicative of the subject having epithelial ovarian cancer, cervical cancer, endometriosis, clear cell renal carcinoma and/or a predisposition to epithelial ovarian cancer, cervical cancer, endometriosis, dear cell renal carcinoma and/or determining whether the ovarian cancer in the subject is primary or secondary ovarian cancer and/or a risk of the disease progression after surgery treatment, and/or an effectiveness of post-surgery chemotherapy. |
